Display options
Cite
Abe H, Natsumeda M, Okada M, et al. MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas. Front Oncol. 2020;9:1568doi: 10.3389/fonc.2019.01568.
Abe, H., Natsumeda, M., Okada, M., Watanabe, J., Tsukamoto, Y., Kanemaru, Y., Yoshimura, J., Oishi, M., Hashizume, R., Kakita, A., & Fujii, Y. (2019). MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas. Frontiers in oncology, 91568. https://doi.org/10.3389/fonc.2019.01568
Abe, Hideaki, et al. "MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas." Frontiers in oncology vol. 9 (2019): 1568. doi: https://doi.org/10.3389/fonc.2019.01568
Abe H, Natsumeda M, Okada M, Watanabe J, Tsukamoto Y, Kanemaru Y, Yoshimura J, Oishi M, Hashizume R, Kakita A, Fujii Y. MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas. Front Oncol. 2020 Jan 21;9:1568. doi: 10.3389/fonc.2019.01568. eCollection 2019. PMID: 32039031; PMCID: PMC6985080.
Copy Download .nbib Format: NLM
Share it on

Front Oncol. 2020 Jan 21;9:1568. doi: 10.3389/fonc.2019.01568. eCollection 2019.

MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas.

Frontiers in oncology

Hideaki Abe, Manabu Natsumeda, Masayasu Okada, Jun Watanabe, Yoshihiro Tsukamoto, Yu Kanemaru, Junichi Yoshimura, Makoto Oishi, Rintaro Hashizume, Akiyoshi Kakita, Yukihiko Fujii

Affiliations

  1. Department of Neurosurgery, Brain Research Institute, Niigata University, Niigata, Japan.
  2. Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, United States.
  3. Department of Biochemistry and Molecular Genetics, Northwestern University Feinberg School of Medicine, Chicago, IL, United States.
  4. Department of Pathology, Brain Research Institute, Niigata University, Niigata, Japan.

PMID: 32039031 PMCID: PMC6985080 DOI: 10.3389/fonc.2019.01568

Abstract

Diffuse midline gliomas (DMGs) show resistance to many chemotherapeutic agents including temozolomide (TMZ). Histone gene mutations in DMGs trigger epigenetic changes including DNA hypomethylation, one of which is a frequent lack of O6-methyl-guanine-DNA methyltransferase (

Copyright © 2020 Abe, Natsumeda, Okada, Watanabe, Tsukamoto, Kanemaru, Yoshimura, Oishi, Hashizume, Kakita and Fujii.

Keywords: DNA hypomethylation; MGMT; diffuse midline gliomas; epigenetics; histone H3 mutation

References

  1. J Neurooncol. 2012 Dec;110(3):305-13 - PubMed
  2. Nat Genet. 2014 May;46(5):444-450 - PubMed
  3. Neurosurgery. 2018 Jul 1;83(1):76-85 - PubMed
  4. Mol Cancer Ther. 2015 Nov;14(11):2560-8 - PubMed
  5. J Neurosurg Pediatr. 2011 May;7(5):522-6 - PubMed
  6. Acta Neuropathol. 2015 Dec;130(6):815-27 - PubMed
  7. Neurol Med Chir (Tokyo). 2017 Jul 15;57(7):331-342 - PubMed
  8. Brain Tumor Pathol. 2013 Jan;30(1):1-7 - PubMed
  9. Neurosurg Rev. 2017 Jul;40(3):469-477 - PubMed
  10. Nat Genet. 2014 May;46(5):457-461 - PubMed
  11. Neuro Oncol. 2014 Jan;16(1):140-6 - PubMed
  12. Neurosurgery. 1989 Aug;25(2):185-94; discussion 194-5 - PubMed
  13. Cancer Res. 1999 Feb 15;59(4):793-7 - PubMed
  14. Lab Invest. 2007 Oct;87(10):1055-65 - PubMed
  15. J Med Chem. 2014 Oct 9;57(19):7900-15 - PubMed
  16. Stem Cells. 2016 Aug;34(8):2016-25 - PubMed
  17. Oncogene. 2007 Jan 11;26(2):186-97 - PubMed
  18. J Neuropathol Exp Neurol. 2015 Aug;74(8):778-90 - PubMed
  19. Acta Neuropathol Commun. 2017 Dec 15;5(1):98 - PubMed
  20. Childs Nerv Syst. 2012 May;28(5):707-13 - PubMed
  21. N Engl J Med. 2005 Mar 10;352(10):997-1003 - PubMed
  22. J Neurooncol. 2012 Jan;106(2):399-407 - PubMed
  23. Cancer Cell. 2017 Oct 9;32(4):520-537.e5 - PubMed
  24. Neuro Oncol. 2018 Oct 9;20(11):1547-1555 - PubMed
  25. J Neurooncol. 2018 Feb;136(3):475-484 - PubMed
  26. Cancer Res. 2017 Aug 1;77(15):4102-4115 - PubMed
  27. Lancet Oncol. 2006 Mar;7(3):241-8 - PubMed
  28. Brain Pathol. 2016 Nov;26(6):713-723 - PubMed
  29. Commun Biol. 2019 May 9;2:156 - PubMed
  30. Nat Genet. 2012 Jan 29;44(3):251-3 - PubMed
  31. Cancer Cell. 2012 Oct 16;22(4):425-37 - PubMed
  32. Neuropathology. 2019 Apr;39(2):71-77 - PubMed
  33. Acta Neuropathol. 2014 Oct;128(4):573-81 - PubMed
  34. DNA Repair (Amst). 2007 Aug 1;6(8):1155-60 - PubMed
  35. Neuro Oncol. 2014 Mar;16(3):352-60 - PubMed
  36. Acta Neuropathol. 2015 May;129(5):669-78 - PubMed
  37. Neuropathology. 2011 Oct;31(5):486-93 - PubMed
  38. Front Oncol. 2019 Feb 08;9:31 - PubMed
  39. Neuropathology. 2015 Aug;35(4):324-35 - PubMed
  40. Cancer Lett. 2017 Aug 1;400:110-116 - PubMed
  41. Nat Genet. 2014 May;46(5):462-6 - PubMed
  42. Acta Neuropathol. 2012 Sep;124(3):439-47 - PubMed
  43. DNA Repair (Amst). 2019 Jun;78:128-141 - PubMed
  44. Cancer Cell. 2013 Nov 11;24(5):660-72 - PubMed
  45. J Neurochem. 2006 Feb;96(3):766-76 - PubMed
  46. Acta Neuropathol Commun. 2019 Jul 25;7(1):119 - PubMed
  47. Biochim Biophys Acta. 1996 Feb 9;1289(1):105-9 - PubMed
  48. Neurol Med Chir (Tokyo). 2018 Jul 15;58(7):290-295 - PubMed

Publication Types